<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Published data on flow cytometry (FCM) in diagnosing <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) varies greatly in analytic methods and interpretational approaches </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the diagnostic utility of the pattern recognition approach by a retrospective review of 180 MDS, 31 myelodysplastic/<z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> (<z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e>), 37 non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cytopenia and 20 <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) cases </plain></SENT>
<SENT sid="2" pm="."><plain>Cases were placed into "positive", "intermediate", and "negative" FCM categories based upon the antigenic aberrations observed on myelomonocytic cells </plain></SENT>
<SENT sid="3" pm="."><plain>By exclusion or inclusion of the intermediate category as indicative of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e>, the overall sensitivity and specificity were 84% and 97% or 98% and 78%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The overall abnormalities detected by FCM correlated with the severity of morphological <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and clonal cytogenetic abnormalities </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> also demonstrated immunophenotypic aberrancy </plain></SENT>
<SENT sid="6" pm="."><plain>Based on a global evaluation of myelomonocytic abnormalities, and recognition of diagnostic pitfalls and caveats, the pattern recognition approach of FCM is sensitive and reliable in diagnosing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and related myeloid diseases </plain></SENT>
</text></document>